Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

GREEN CROSS CORPORATION

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects

Phase 2

Completed

Conditions: Influenza, Human

Interventions: Biological: GCFLU Quadrivalent
Biological: GC3114

First Posted Date: 2018-09-05

Last Posted Date: 2019-01-04

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 105

Registration Number: NCT03657719

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102

Phase 2

Conditions: Hepatitis B Infection

Interventions: Biological: GC1102 80,000 IU
Biological: GC1102 100,000 IU
Biological: I.V HBIG

First Posted Date: 2018-05-08

Last Posted Date: 2020-01-30

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 186

Registration Number: NCT03519113

Locations: 🇰🇷
Seoul Asan Medical Center, Seoul, Korea, Republic of

Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency

Phase 3

Withdrawn

Conditions: Primary Immune Deficiency Disorder

Interventions: Biological: Immunoglobulin

First Posted Date: 2018-04-10

Last Posted Date: 2020-07-07

Lead Sponsor: Green Cross Corporation

Registration Number: NCT03492710

A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy

Phase 1

Completed

Conditions: Metastatic Colorectal Cancer
Solid Tumor

Interventions: Drug: irinotecan
Drug: FOLFIRI

First Posted Date: 2018-03-06

Last Posted Date: 2022-03-03

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 53

Registration Number: NCT03454620

Locations: 🇰🇷
Chonnam National University Hwasun Hospital, Chŏnam, Korea, Republic of
🇰🇷
National Cancer Center, Gyeonggi-do, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of

and more 3 locations

A Study of MG1111 in Healthy Children

Phase 2

Completed

Conditions: Healthy Children

Interventions: Drug: Varicella Vaccine

First Posted Date: 2017-12-18

Last Posted Date: 2021-05-14

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 814

Registration Number: NCT03375502

Locations: 🇰🇷
The catholic university of Korea, Seoul st. mary's hospital, Banpo-dong, Seoul, Korea, Republic of

Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) in Healthy Adults

Phase 1

Conditions: Tuberculosis

Interventions: Biological: GC3107

First Posted Date: 2017-12-06

Last Posted Date: 2017-12-18

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 20

Registration Number: NCT03363178

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults

Phase 1

Completed

Conditions: Influenza, Human

Interventions: Biological: GCFLU Quadrivalent
Biological: GC3114

First Posted Date: 2017-11-29

Last Posted Date: 2018-11-19

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 40

Registration Number: NCT03357263

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age

Phase 3

Conditions: Influenza Vaccine

Interventions: Biological: GC3110A
Biological: GCFLU Pre-filled syringe inj.

First Posted Date: 2017-09-18

Last Posted Date: 2017-09-18

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 260

Registration Number: NCT03285997

Locations: 🇰🇷
The Catholic Univ.of Korea Seoul St.Mary's Hospital, Seoul, Korea, Republic of

A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older

Phase 3

Completed

Conditions: Influenza, Human

Interventions: Biological: GC3110A vaccine

First Posted Date: 2016-09-28

Last Posted Date: 2017-05-30

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 274

Registration Number: NCT02917304

Locations: 🇰🇷
The Catholic Univ. of Korea Daejeon St.Mary's Hospital, Daejeon, Korea, Republic of
🇰🇷
Soon Chun Hyang University Bucheon Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷
The Catholic Univ.of Korea Bucheon St.Mary's Hospital, Gyeonggi-do, Korea, Republic of

and more 7 locations

A Study to Evaluate Efficacy and Safety of GC3110B in Healthy Adults

Phase 3

Conditions: Influenza, Human

Interventions: Biological: GC3110B vaccine
Biological: GCFLU Quadrivalent Inj. vaccine

First Posted Date: 2016-09-27

Last Posted Date: 2016-09-29

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 414

Registration Number: NCT02915809

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy